| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.07B | -9.4% |
| Gross profit | ¥0.05B | — |
| Operating income | ¥0.01B | — |
| Net income | ¥0.01B | -6.1% |
| Gross margin | 69.9% | Net margin 14.6% |
| Revenue Q/Q | -41.3% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.02B | 30.1% |
| R&D | ¥0.02B | 26.8% |
| SG&A | ¥0.03B | 36.1% |
| Tax & other | ¥-0.00B | -1.2% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
慈星股份 ・ 宜通世纪 ・ ST任子行 ・ 天山生物 ・ 戴维医疗 ・ 掌趣科技 ・ 珈伟新能 ・ 博晖创新 ・ 麦捷科技 ・ 海达股份 ・ 同大股份 ・ 硕贝德
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies